Compare KE Holdings Inc (BEKE) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KE Holdings Inc vs Summit Therapeutics Inc — how do they compare? KE Holdings Inc trades at $17.23 (market cap $17.83B), while Summit Therapeutics Inc trades at $15.04 (market cap $12.01B). The key difference: KE Holdings Inc is the larger of the two by market cap, and KE Holdings Inc pays a 1.71% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| BEKE | SMMT | |
|---|---|---|
Market Cap | $17.83B | $12.01B |
Sector | Technology | Health |
52-Week High | $20.36 | $29.32 |
52-Week Low | $14.26 | $13.05 |
Enterprise Value | $13.61B | $11.43B |
Dividend Yield | 1.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BEKE trades at $16.07, up 3.21% today, with a bullish technical signal and strong analyst consensus (91.67% buy ratings). Recent Q1 2026 earnings beat expectations with EPS of $0.20 versus $0.14 forecast, driven by cost controls and operational efficiency. Revenue for 2025 was $94.58 billion, with a net income margin of 3.76%, though cash flow from operations was negative $376.17 million.
The outlook is positive given earnings momentum and oversold conditions suggesting a potential reversal. Risks include reliance on China's property market and volatile cash flows. With high institutional support and improving profitability, the stock presents a growth opportunity amid market recovery prospects.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About KE Holdings Inc
KE Holdings (Beike) is China’s leading platform for housing transactions and services. It operates the Lianjia brand and uses data-driven technology to facilitate home sales, rentals, and home renovation services.
Read more on BEKE →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
